Group One Trading
RANI icon

Group One Trading’s Rani Therapeutics RANI Stock Holding History

Group One Trading’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$152 Hold
200
– – ﹤0.01% 7385
2026
Q1 		$147 Sell
200
-100
-33% -$128 ﹤0.01% 7413
2025
Q4 		$405 Buy
+300
New +$453 ﹤0.01% 7829
2025
Q2 		– Sell
-400
Closed -$504 – 8534
2025
Q1 		$504 Sell
400
-9,500
-96% -$14.1K ﹤0.01% 7280
2024
Q4 		$13.6K Buy
+9,900
New +$20.8K ﹤0.01% 5934

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Group One Trading's RANI Position: Q2 2026 in Review

Group One Trading opened a new position in Rani Therapeutics (RANI) in Q2 2026: 3,724 shares worth $2.83K. The stake represents ﹤0.01% of the portfolio and ranks #6932 among its holdings.

68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Group One Trading held 3,724 shares of Rani Therapeutics worth $2.83K as of Q2 2026.
  • Rani Therapeutics was a new Group One Trading position in Q2 2026.
  • Rani Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #6932 holding.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.